SK99994A3 - Pharmaceutical composition for treatment of mental illnesses connected with autoimmune reaction - Google Patents

Pharmaceutical composition for treatment of mental illnesses connected with autoimmune reaction Download PDF

Info

Publication number: SK99994A3
Authority: SK; Slovakia
Prior art keywords: vaccae; treatment; infection; antigenic; material derived
Prior art date: 1992-02-21

Application number

SK999-94A

Other languages

English (en)

Slovak (sk)

Inventor

John L Stanford

Graham A W Rook

Original Assignee

Univ London

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-02-21

Filing date

1993-02-19

Publication date

1995-05-10

1993-02-19 Application filed by Univ London filed Critical Univ London

1995-05-10 Publication of SK99994A3 publication Critical patent/SK99994A3/sk

Links

238000011282 treatment Methods 0.000 title claims abstract description 24
208000020016 psychiatric disease Diseases 0.000 title claims description 12
230000001363 autoimmune Effects 0.000 title claims description 7
238000006243 chemical reaction Methods 0.000 title claims description 5
239000008194 pharmaceutical composition Substances 0.000 title 1
241000187644 Mycobacterium vaccae Species 0.000 claims abstract description 38
239000000463 material Substances 0.000 claims abstract description 20
230000001404 mediated effect Effects 0.000 claims abstract description 15
230000000890 antigenic effect Effects 0.000 claims abstract description 14
230000004957 immunoregulator effect Effects 0.000 claims abstract description 13
201000008827 tuberculosis Diseases 0.000 claims abstract description 7
208000019553 vascular disease Diseases 0.000 claims abstract description 6
206010001935 American trypanosomiasis Diseases 0.000 claims abstract description 5
206010012601 diabetes mellitus Diseases 0.000 claims abstract description 5
208000024699 Chagas disease Diseases 0.000 claims abstract description 4
238000011321 prophylaxis Methods 0.000 claims abstract 3
208000015181 infectious disease Diseases 0.000 claims description 19
244000005700 microbiome Species 0.000 claims description 16
239000003814 drug Substances 0.000 claims description 14
229940124597 therapeutic agent Drugs 0.000 claims description 12
230000006472 autoimmune response Effects 0.000 claims description 10
201000010099 disease Diseases 0.000 claims description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
208000037581 Persistent Infection Diseases 0.000 claims description 5
206010046851 Uveitis Diseases 0.000 claims description 5
238000000034 method Methods 0.000 claims description 4
238000002360 preparation method Methods 0.000 claims description 3
230000005180 public health Effects 0.000 claims description 2
239000003085 diluting agent Substances 0.000 description 6
239000000203 mixture Substances 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
208000027531 mycobacterial infectious disease Diseases 0.000 description 5
201000000980 schizophrenia Diseases 0.000 description 5
210000004027 cell Anatomy 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
239000000725 suspension Substances 0.000 description 4
229920001817 Agar Polymers 0.000 description 3
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 3
206010024229 Leprosy Diseases 0.000 description 3
206010062207 Mycobacterial infection Diseases 0.000 description 3
239000008272 agar Substances 0.000 description 3
206010039073 rheumatoid arthritis Diseases 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
239000007787 solid Substances 0.000 description 3
241000894006 Bacteria Species 0.000 description 2
208000035143 Bacterial infection Diseases 0.000 description 2
208000009525 Myocarditis Diseases 0.000 description 2
206010037075 Protozoal infections Diseases 0.000 description 2
208000034189 Sclerosis Diseases 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000000427 antigen Substances 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
230000002917 arthritic effect Effects 0.000 description 2
210000003719 b-lymphocyte Anatomy 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
208000022362 bacterial infectious disease Diseases 0.000 description 2
239000003618 borate buffered saline Substances 0.000 description 2
239000000872 buffer Substances 0.000 description 2
230000008076 immune mechanism Effects 0.000 description 2
239000002955 immunomodulating agent Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
230000002085 persistent effect Effects 0.000 description 2
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
229920000053 polysorbate 80 Polymers 0.000 description 2
208000002574 reactive arthritis Diseases 0.000 description 2
208000030507 AIDS Diseases 0.000 description 1
206010003267 Arthritis reactive Diseases 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
208000020925 Bipolar disease Diseases 0.000 description 1
201000004569 Blindness Diseases 0.000 description 1
GUTLYIVDDKVIGB-OUBTZVSYSA-N Cobalt-60 Chemical compound [60Co] GUTLYIVDDKVIGB-OUBTZVSYSA-N 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
102000004889 Interleukin-6 Human genes 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
241000187472 Mycobacterium chitae Species 0.000 description 1
241000187491 Mycobacterium nonchromogenicum Species 0.000 description 1
206010028851 Necrosis Diseases 0.000 description 1
208000012654 Primary biliary cholangitis Diseases 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
208000033464 Reiter syndrome Diseases 0.000 description 1
208000021386 Sjogren Syndrome Diseases 0.000 description 1
206010041591 Spinal osteoarthritis Diseases 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
208000028683 bipolar I disease Diseases 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
208000037976 chronic inflammation Diseases 0.000 description 1
208000037893 chronic inflammatory disorder Diseases 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000001816 cooling Methods 0.000 description 1
230000034994 death Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
210000000852 deltoid muscle Anatomy 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
230000006872 improvement Effects 0.000 description 1
229940100601 interleukin-6 Drugs 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
230000035800 maturation Effects 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
238000001050 pharmacotherapy Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
208000028172 protozoa infectious disease Diseases 0.000 description 1
230000005855 radiation Effects 0.000 description 1
201000000306 sarcoidosis Diseases 0.000 description 1
238000007790 scraping Methods 0.000 description 1
241000894007 species Species 0.000 description 1
208000005801 spondylosis Diseases 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
229960001005 tuberculin Drugs 0.000 description 1
102000003390 tumor necrosis factor Human genes 0.000 description 1
230000002792 vascular Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Immunology (AREA)
Pulmonology (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Saccharide Compounds (AREA)
External Artificial Organs (AREA)
Soil Working Implements (AREA)
Storage Of Fruits Or Vegetables (AREA)

SK999-94A 1992-02-21 1993-02-19 Pharmaceutical composition for treatment of mental illnesses connected with autoimmune reaction SK99994A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB929203814A GB9203814D0 (en)	1992-02-21	1992-02-21	Treatment of long term auto-immune conditions
PCT/GB1993/000351 WO1993016727A1 (en)	1992-02-21	1993-02-19	Mycobacterium vaccae for treatment of long term autoimmune conditions

Publications (1)

Publication Number	Publication Date
SK99994A3 true SK99994A3 (en)	1995-05-10

Family

ID=10710862

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK999-94A SK99994A3 (en)	1992-02-21	1993-02-19	Pharmaceutical composition for treatment of mental illnesses connected with autoimmune reaction

Country Status (24)

Country	Link
US (1)	US5885588A (de)
EP (2)	EP0630259B1 (de)
JP (1)	JPH07506093A (de)
KR (1)	KR100275862B1 (de)
AT (2)	ATE192046T1 (de)
AU (2)	AU675421B2 (de)
BG (1)	BG99054A (de)
BR (1)	BR9305946A (de)
CA (1)	CA2130117A1 (de)
CZ (1)	CZ282651B6 (de)
DE (2)	DE69309915T2 (de)
DK (2)	DK0763361T3 (de)
ES (2)	ES2104131T3 (de)
FI (1)	FI943849A0 (de)
GB (1)	GB9203814D0 (de)
GR (2)	GR3024113T3 (de)
HU (1)	HU218347B (de)
NO (1)	NO311169B1 (de)
NZ (1)	NZ249518A (de)
RO (1)	RO117833B1 (de)
RU (1)	RU2124367C1 (de)
SK (1)	SK99994A3 (de)
UA (1)	UA35583C2 (de)
WO (1)	WO1993016727A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9406301D0 (en) *	1994-03-30	1994-05-25	Univ London	Immunotherapeutic agent and its use
IL110011A (en) *	1994-06-13	2004-09-27	Yeda Res & Dev	Pharmacological preparations for the treatment of schizophrenia
GB9505658D0 (en) *	1995-03-21	1995-05-10	Univ London	Hormone and growth factor mimetics
US6056964A (en) *	1995-03-29	2000-05-02	Stanford Rook Limited	Immunotherapeutic agent and its use
US6160093A (en) *	1996-08-29	2000-12-12	Genesis Researth And Development Corporation Limited	Compounds and methods for treatment and diagnosis of mycobacterial infections
US5985287A (en) *	1996-08-29	1999-11-16	Genesis Research And Development Corporation Limited	Compounds and methods for treatment and diagnosis of mycobacterial infections
AU741016B2 (en) *	1996-08-29	2001-11-22	Genesis Research And Development Corporation Limited	Compounds and methods for treatment and diagnosis of mycobacterial infections
US6406704B1 (en)	1996-08-29	2002-06-18	Genesis Research And Development Corporation Limited	Compounds and methods for treatment and diagnosis of mycobacterial infections
US6284255B1 (en) *	1996-08-29	2001-09-04	Genesis Research & Development Corporation Limited	Compounds and methods for treatment and diagnosis of mycobacterial infections
US6878377B2 (en)	1996-12-18	2005-04-12	Stanford Rook Limited	Mycobacterium vaccae for down-regulation of the Th2 activity of the immune system
JP4358306B2 (ja) *	1996-12-18	2009-11-04	スタンフォードルークリミティド	免疫系のＴｈ２活性のダウン−レギュレーションのためのマイコバクテリア・ワクチン
RU2137137C1 (ru) *	1997-12-03	1999-09-10	Научно-исследовательский институт по изучению лепры	Способ определения m.leprae у больных с регрессом заболевания
CA2315539A1 (en) *	1997-12-23	1999-07-01	Genesis Research & Development Corporation Limited	Compositions derived from mycobacterium vaccae and methods for their use
US6328978B1 (en)	1997-12-23	2001-12-11	Genesis Research & Development Corp. Ltd.	Methods for the treatment of immunologically-mediated skin disorders
US5968524A (en) *	1997-12-23	1999-10-19	Genesis Research & Development Corp.	Methods and compounds for the treatment of immunologically-mediated psoriasis
US6350457B1 (en)	1999-06-02	2002-02-26	Genesis Research & Development Corporation Limited	Methods and compounds for the treatment of immunologically-mediated diseases using mycobacterium vaccae
AU6896300A (en) *	1999-08-06	2001-03-05	Corixa Corporation	Vaccines for the treatment of autoimmune disease
GB0010496D0 (en) *	2000-04-28	2000-06-14	Stanford Rook Ltd	Treatment of conditions of the central nervous system
GB0106985D0 (en) *	2001-03-20	2001-05-09	Stanford Rook Ltd	Immunotherapeutic agent
GB0106986D0 (en) *	2001-03-20	2001-05-09	Stanford Rook Ltd	Immunotherapeutic agent
AR046583A1 (es)	2003-11-14	2005-12-14	Ucl Biomedica Plc	Uso de una composicion inmunomoduladora

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8404280D0 (en) *	1984-02-17	1984-03-21	Stanford J L	Biological preparations
IL71683A0 (en) *	1984-04-27	1984-09-30	Yeda Res & Dev	Pharmaceutical compositions for treating arthritis type diseases comprising fractions obtained from mycobacteria
GB8919321D0 (en) *	1989-08-25	1989-10-11	Univ London	Treatment of chronic inflammatory conditions
ATE154759T1 (de) *	1990-11-08	1997-07-15	Univ London	Mycobacterium als adjuvans für antigene

1992
- 1992-02-21 GB GB929203814A patent/GB9203814D0/en active Pending
1993
- 1993-02-19 CA CA002130117A patent/CA2130117A1/en not_active Abandoned
- 1993-02-19 EP EP93905460A patent/EP0630259B1/de not_active Expired - Lifetime
- 1993-02-19 NZ NZ249518A patent/NZ249518A/en unknown
- 1993-02-19 RO RO94-01401A patent/RO117833B1/ro unknown
- 1993-02-19 DE DE69309915T patent/DE69309915T2/de not_active Expired - Fee Related
- 1993-02-19 ES ES93905460T patent/ES2104131T3/es not_active Expired - Lifetime
- 1993-02-19 DK DK96201912T patent/DK0763361T3/da active
- 1993-02-19 WO PCT/GB1993/000351 patent/WO1993016727A1/en not_active Ceased
- 1993-02-19 UA UA94095856A patent/UA35583C2/uk unknown
- 1993-02-19 DK DK93905460.7T patent/DK0630259T3/da active
- 1993-02-19 AU AU36377/93A patent/AU675421B2/en not_active Ceased
- 1993-02-19 SK SK999-94A patent/SK99994A3/sk unknown
- 1993-02-19 JP JP5514636A patent/JPH07506093A/ja not_active Ceased
- 1993-02-19 CZ CZ942023A patent/CZ282651B6/cs not_active IP Right Cessation
- 1993-02-19 KR KR1019940702920A patent/KR100275862B1/ko not_active Expired - Fee Related
- 1993-02-19 RU RU94045825A patent/RU2124367C1/ru not_active IP Right Cessation
- 1993-02-19 AT AT96201912T patent/ATE192046T1/de not_active IP Right Cessation
- 1993-02-19 AT AT93905460T patent/ATE151641T1/de not_active IP Right Cessation
- 1993-02-19 ES ES96201912T patent/ES2145968T3/es not_active Expired - Lifetime
- 1993-02-19 EP EP96201912A patent/EP0763361B1/de not_active Expired - Lifetime
- 1993-02-19 US US08/290,813 patent/US5885588A/en not_active Expired - Fee Related
- 1993-02-19 BR BR9305946A patent/BR9305946A/pt not_active Application Discontinuation
- 1993-02-19 DE DE69328503T patent/DE69328503T2/de not_active Expired - Fee Related
- 1993-02-19 HU HU9402422A patent/HU218347B/hu not_active IP Right Cessation
1994
- 1994-08-22 NO NO19943082A patent/NO311169B1/no not_active IP Right Cessation
- 1994-08-22 FI FI943849A patent/FI943849A0/fi not_active Application Discontinuation
- 1994-09-21 BG BG99054A patent/BG99054A/xx unknown
1996
- 1996-11-20 AU AU71887/96A patent/AU706122B2/en not_active Ceased
1997
- 1997-07-16 GR GR970401763T patent/GR3024113T3/el unknown
2000
- 2000-06-23 GR GR20000401468T patent/GR3033772T3/el not_active IP Right Cessation

Also Published As

Publication number	Publication date
HUT69941A (en)	1995-09-28
GR3033772T3 (en)	2000-10-31
GB9203814D0 (en)	1992-04-08
AU706122B2 (en)	1999-06-10
DE69328503D1 (de)	2000-05-31
DK0630259T3 (da)	1997-09-15
EP0630259B1 (de)	1997-04-16
NZ249518A (en)	1997-07-27
CZ202394A3 (en)	1995-02-15
RU94045825A (ru)	1997-02-20
NO943082D0 (no)	1994-08-22
EP0763361A2 (de)	1997-03-19
KR100275862B1 (ko)	2000-12-15
NO943082L (no)	1994-10-17
AU675421B2 (en)	1997-02-06
CA2130117A1 (en)	1993-09-02
ES2145968T3 (es)	2000-07-16
KR950700755A (ko)	1995-02-20
DE69309915D1 (de)	1997-05-22
UA35583C2 (uk)	2001-04-16
EP0763361B1 (de)	2000-04-26
ATE192046T1 (de)	2000-05-15
ES2104131T3 (es)	1997-10-01
BR9305946A (pt)	1997-10-21
AU7188796A (en)	1997-02-06
NO311169B1 (no)	2001-10-22
DK0763361T3 (da)	2000-08-07
DE69309915T2 (de)	1997-07-24
ATE151641T1 (de)	1997-05-15
RO117833B1 (ro)	2002-08-30
RU2124367C1 (ru)	1999-01-10
HU9402422D0 (en)	1994-10-28
FI943849A0 (fi)	1994-08-22
DE69328503T2 (de)	2000-08-24
BG99054A (en)	1995-08-28
AU3637793A (en)	1993-09-13
EP0630259A1 (de)	1994-12-28
EP0763361A3 (de)	1997-03-26
JPH07506093A (ja)	1995-07-06
HU218347B (hu)	2000-08-28
CZ282651B6 (cs)	1997-08-13
GR3024113T3 (en)	1997-10-31
WO1993016727A1 (en)	1993-09-02
US5885588A (en)	1999-03-23

Publication	Publication Date	Title
US5833996A (en)	1998-11-10	Treatment of psoriasis using dead cells of Mycobacterium vaccae
SK99994A3 (en)	1995-05-10	Pharmaceutical composition for treatment of mental illnesses connected with autoimmune reaction
US4724144A (en)	1988-02-09	Immuno-therapeutic composition of killed cells from mycobacterium vaccae
EP0556241B1 (de)	1996-01-10	Mycobacterium vaccae in der behandlung von uveitis
KR100272743B1 (ko)	2000-11-15	Hiv 감염의 치료에 유용한 미코박테리움 바케로부터의 항원물질
CA2064029C (en)	1998-12-29	Use of mycobacterium vaccae in the prevention of aids
US6210684B1 (en)	2001-04-03	Method for delaying the onset of AIDS
HK1011289B (en)	2000-04-14	Therapeutic agent from mycobacterium vaccae and its use against hiv infection with aids